Dapagliflozin, sildenafil and their combination in monocrotaline-induced pulmonary arterial hypertension

BACKGROUND: Dapagliflozin, a selective inhibitor of sodium-glucose cotransporter 2 (SGLT2), can reduce cardiovascular events and mortality in patients with heart failure. A number of mechanisms have been proposed to explain the beneficial effects of SGLT2 inhibitors. The purpose of this study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Yi, Tan, Siyuan, Li, Minqi, Tang, Yijin, Xu, Xiaoping, Zhang, Qinghai, Fu, Qinghua, Tang, Mingxiang, He, Jin, Zhang, Yi, Zheng, Zhaofen, Peng, Jianqiang, Zhu, Tengteng, Xie, Wenlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006601/
https://www.ncbi.nlm.nih.gov/pubmed/35413880
http://dx.doi.org/10.1186/s12890-022-01939-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9006601/
https://www.ncbi.nlm.nih.gov/pubmed/35413880
http://dx.doi.org/10.1186/s12890-022-01939-7

Ejemplares similares